The 21st Century Cures Act - Will It Take Us Back in Time?

被引:70
作者
Avorn, Jerry [1 ]
Kesselheim, Aaron S.
机构
[1] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law PORTAL, Boston, MA 02115 USA
关键词
APPROVAL; FDA;
D O I
10.1056/NEJMp1506964
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:2473 / 2475
页数:3
相关论文
共 4 条
[1]   Approval of a Tuberculosis Drug Based on a Paradoxical Surrogate Measure [J].
Avorn, Jerry .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (13) :1349-1350
[2]   Strength of Study Evidence Examined by the FDA in Premarket Approval of Cardiovascular Devices [J].
Dhruva, Sanket S. ;
Bero, Lisa A. ;
Redberg, Rita F. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (24) :2679-2685
[3]   Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012 [J].
Downing, Nicholas S. ;
Aminawung, Jenerius A. ;
Shah, Nilay D. ;
Krumholz, Harlan M. ;
Ross, Joseph S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (04) :368-377
[4]   The Roles Of Academia, Rare Diseases, And Repurposing In The Development Of The Most Transformative Drugs [J].
Kesselheim, Aaron S. ;
Tan, Yongtian Tina ;
Avorn, Jerry .
HEALTH AFFAIRS, 2015, 34 (02) :286-293